873016-31-0

Upstream product

• 873016-30-9 4,5,7,8-tetrahydro-thieno[2,3-d]azepine-6-carboxylic acid ethyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 102997-01-3 5,6,7,8-tetrahydro-4H-thieno<2,3-d>azepine 
• 1138820-51-5 ethyl (2-chloro-2-oxoethyl)(2-(thiophen-2-yl)ethyl)carbamate 
• 873016-29-6 ethyl 4-oxo-7,8-dihydro-4H-thieno[2,3-d]azepine-6(5H)-carboxylate 
• 951259-18-0 2-((ethoxyformyl)(2-(thiophen-2-yl)ethyl)amino)acetic acid 
• 1056159-24-0 ethyl 2-((ethoxyformyl)(2-(thiophen-2-yl)ethyl)amino)acetate 
• 114550-00-4 ethyl 2-((2-(thiophen-2-yl)ethyl)amino)acetate 
• 30433-91-1 [2-(2-thyenyl)ethyl]amine 

Relevant academic research and scientific papers

RESORCINOL DERIVATIVE AS HSP90 INHIBITOR

The present invention relates to a compound represented by formula (I) of a resorcinol derivative as an HSP90 inhibitor or pharmaceutically accepted salts thereof. The compound in the present invention has the activity of inhibiting heat shock protein HSP90. Therefore, the compound in the present invention is used to treat proliferative diseases such as cancer and neurodegenerative diseases. The present invention further provides the compounds and preparation methods for pharmaceutical compositions comprising the compounds, a method for treating diseases, and pharmaceutical compositions comprising the compounds.

Substituted azepine derivatives as serotonin receptor modulators

The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).